Dr. Kim A. Margolin, MD

Dr. Margolin practices at Providence Saint John's Health Center in Santa Monica, California, part of Providence Health & Services.

Dr. Margolin's NPI, 1912014713, was assigned on August 25, 2006. Dr. Margolin graduated from Stanford University School Of Medicine in 1979. Dr. Margolin's California license number on file is G48714.

Dr. Margolin's primary practice is Providence Saint John's Health Center, at 2121 Santa Monica Blvd, Santa Monica, CA 90404 in Los Angeles County. The practice phone is (310) 829-5511.

Dr. Margolin's primary practice is Providence Saint John's Health Center in Santa Monica, California, part of Providence Health & Services. The medical group on file is Saint John's Physician Partners.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Margolin practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Margolin's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Margolin is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Margolin's licenses on file in 2 states: California and Washington.

Dmand AI lists chronic leukemia, lymphoma and prostate cancer among the conditions Dr. Margolin treats.

CMS data shows 522 Medicare services from Dr. Margolin across 6 procedure codes in 2024, for 86 Medicare patients. Medicare paid $35,860 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 86 Medicare patients who saw Dr. Margolin in 2024. The largest group is 65 to 74, with 37 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Margolin's median patient age at 75, with 46% women.

In 2024, Dr. Margolin wrote 158 Medicare Part D claims for 29 patients. 82% of them were for generic drugs. CMS names the drug for 33 of them, across 2 drugs with 11 or more claims each, at $211 in total drug cost. In 2023, CMS named 38 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Margolin for performance year 2024, reported as part of a group. Dr. Margolin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Margolin as offering telehealth.

Dmand AI links 251 papers to Dr. Margolin, published from 2002 to 2025. 2015 was the busiest year, with 10. The most frequent topics are Melanoma, Antineoplastic Combined Chemotherapy Protocols and Interleukin-2. Dr. Margolin has published most often in J Clin Oncol. Dr. Margolin's most frequent co-authors are Lucille Leong, MD, George Somlo, MD and Robert Morgan, MD.

Dmand AI links Dr. Margolin to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Adrenocortical Carcinoma, Carcinoma, Renal Cell and Adenoma, Islet Cell. Open Payments lists research payments to Dr. Margolin that name 1 trial.

CMS Open Payments shows 100 general payments to Dr. Margolin from 21 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 90% of the total. Pfizer Inc. paid the most, $42,536. It also lists 11 research payments totaling $5,888 from 2023 to 2025, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Margolin.

Dr. Margolin graduated from Stanford University School Of Medicine in 1979.

Dr. Margolin is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.